Presidential Symposium | Recent Research Revolutions and Their Impact on Epilepsy Patient Care
Saturday, December 4, 2021
-
You may need to log in to view video on this page.
OVERVIEW:
The 2021 AES Presidential Symposium introduces recent advances in research on disease mechanisms, and interprets findings and progress through the lens of a practicing neurologist in the epilepsy clinic. These advances have the potential to impact patient care in the near term.
Advances to be highlighted include:
- Deep behavioral phenotyping
- Single neuron omics
- Electrical recordings from neurons using high density large-scale arrays of electrodes
- "Big data" strategies for integrating massive data sets in the clinical setting
The symposium opens with a case report presented by a practicing neurologist, and closes by highlighting how each of these research advances could enhance the diagnosis and treatment of the patient under discussion.
Learning Objectives:
Following participation in this activity, participants will be able to:
- Describe the relevance of recent research revolutions in transforming clinical practice
- Apply this understanding of the clinical relevance of research advances to further knowledge integration
- Integrate the multifaceted current research advances into a synthesized view of future clinic practice
Program:
Chair: Douglas A. Coulter, PhD
Introduction | Douglas A. Coulter, PhD
Deep Behavioral Phenotyping in Analysis of Epilepsy | Ivan Soltesz, PhD
Omics Approaches in Epilepsy Research: From Single Cells to Post-Translational Modifications | Susanne Schoch, PhD
Integrated, Large-Scale Electrode Array Neurophysiologic Recordings in Epilepsy | Jennifer Gelinas, MD, PhD
Big Data Approaches in Neurologic Disease Diagnosis and Therapy | Brian Litt, MD
Patient Case Report | Ethan Goldberg, MD, PhD, Fritz E. Dreifuss Award
Panel Discussion | All Faculty
Education Credit:
2.75 Nursing Contact Hours
2.75 CME
This educational activity is supported in part by education grants from: Eisai Inc., Supernus Pharmaceuticals, Inc., and UCB, Inc.